High Inflammation Rates Found in U.S. Heart Failure
Half of U.S. patients with heart failure show elevated markers of cardiovascular inflammation in a new analysis.
Updated on Oct. 14, 2026 in Heart Disease
Live Poll
Do you trust that current medical research effectively addresses heart inflammation in patients?
A recent subanalysis of the POSEIDON registry revealed that over 44% to 50% of U.S. heart failure patients exhibit elevated high-sensitivity C-reactive protein (hsCRP) levels. This research highlights the high prevalence of cardiovascular inflammation among those managing these conditions.
Why it matters
Identifying inflammation is critical for assessing cardiovascular risk, as it often occurs alongside conditions like obesity, diabetes, and chronic kidney disease. This analysis underscores the need to determine which patients might benefit from targeted anti-inflammatory therapies as treatment standards evolve.
In a cross-sectional subanalysis of the POSEIDON registry involving 18,904 adults, researchers measured hsCRP levels to assess inflammatory risk. The data showed that U.S. participants had consistently higher rates of inflammation compared to the global cohort across all heart failure types.
The players
Novo Nordisk
A pharmaceutical company focused on diabetes, obesity, and cardiovascular disease therapies.
The details
High-sensitivity C-reactive protein is a blood-based marker that signals the presence of systemic inflammation, which is often exacerbated by underlying conditions like chronic kidney disease and obesity. When inflammation is high, it typically correlates with increased levels of IL-6 and NT-proBNP, biological indicators that reflect ongoing strain on the heart muscle. This study aimed to map the prevalence of this inflammatory state in patients with different forms of heart failure, such as HFrEF and HFpEF.
Timeline
Participants were recruited into the POSEIDON study between 2023 and 2025.
Novo Nordisk ceased the HERMES and ATHENA trials in September 2026.
Findings were presented at a Heart Failure Society conference in October 2026.
Health Landscape
This research utilizes the POSEIDON registry to document the intersection of inflammation and heart failure outcomes. The findings follow recent clinical failures, such as the ZEUS trial, which highlight the complexity of targeting inflammation to reduce cardiovascular events.
If you are managing heart failure, it is worth discussing the role of systemic inflammation and blood markers like hsCRP with your cardiologist. These markers can provide additional context regarding your cardiovascular health, especially if you have comorbidities like diabetes or obesity.
The takeaway
Systemic inflammation is highly prevalent in U.S. patients with heart failure and may complicate disease management. Consider asking your physician about your inflammatory markers during your next checkup to better understand your specific cardiovascular risk profile.
Further reading
For more on managing heart conditions, visit our Heart Disease section.
Source note: This article includes information reported by MedPage Today.
Live Poll
Do you trust that current medical research effectively addresses heart inflammation in patients?
